Food
Tel: 0086 571 87206574
Email: service@cirs-group.com
Global New Food Ingredients
USA
China
NHC New Food Raw Material Registration in China
NHC New Food Additive Registration in China
Genetically Modified Microorganism Food Additive Registration in China
Genetically Modified Microorganism New Food Raw Material Application
EU
EU Food Additive Authorization Application
EU Food Enzyme and Food Enzyme Preparation Application
EU Novel Food Application
Australia and New Zealand
South America
South Korea
Global Dietary Supplements and Food & Beverages
USA
US FDA Dietary Supplement Structure/Function Claim Notification
US FDA Registration of Food Facilities
US Food Label/Advertisement Information Review
China
Global Feed and Pet Food
China
Official Consultation Service for Feed Ingredient and Feed Additive Approval in China
New Feed and New Feed Additive Application in China
Label Review Service of Pet Food in China
MARA Imported Feed and Pet Food Registration
GACC Registration Service of Overseas Manufacturer of Imported Feed and Pet Food
USA
EU
Global Food Contact Materials
China
New Food Contact Substance Registration in China
China Declaration of Compliance (DoC) for FCM
Formula Compliance Analysis
Food Product National Standards Routine Testing Items
Food Contact Materials (FCM) Migration Test
USA
China Health Food/Dietary Supplements
SAMR Health Food (Dietary Supplement) Registration/Filing in China
China Health Food Registration Renewal
China Health Food Change Registration
Health Food Technology Transfer Registration in China
China Health Food Formula and Process Research and Development
China Health Food Testing Service
Renewal of Registration Certificate Service for “Dual-no” Health Food
Application of New Health Functions in China
China Infant Formula and FSMP
SAMR Infant Formula Milk Powder Registration
SAMR Food for Special Medical Purpose (FSMP) Registration
Foods for Special Medical Purposes (FSMP) Formula Development and Process Validation
Infant Formula Milk Powder Formula Development and Process Validation
Foods for Special Medical Purposes (FSMP) Testing Service
China Infant Formula Milk Powder Testing Service
Pursuant to the Announcement (No.38, 2023) jointly issued by the State Administration for Market Regulation, National Health Commission, and National Administration of Traditional Chinese Medicine regarding the Directory of Health Functions Permitted for Health Food Claims for Non-Nutrient Supplements (2023 Edition) (hereinafter referred to as “the Claims”), all registered non-nutrient supplement health foods will be regulated in accordance with the Administrative Measures for the Catalog of Health Food Ingredients and Health Functions and the Claims for five years from the date of this announcement.
On October 2, 2025, UK has launched a public consultation on plans to completely prohibit the use of bisphenol A (BPA), other bisphenol analogues, and their derivatives in food contact materials.
China NHC issued notifications regarding the acceptance of “three new foods”. The applications for 4 new food additives have been received.
On October 17, 2025, Japan’s Consumer Affairs Agency, through its Food Sanitation Standards Review Section, announced a public consultation on two draft amendments related to materials that come into contact with food. The drafts include revisions to Monomers and Other Starting Materials Specified in Table 1 of Appendix 1 of the Standards for Foods, Additives, etc. and the Guidelines for the Use of Recycled Materials as Raw Materials in the Manufacture of Food Utensils and Container Packaging.
In recent years, the enthusiasm for GRAS Notices to the U.S. FDA has remained strong. From July 2025 to the present, the FDA has released a large-scale update to the GRAS inventory. CIRS Group has conducted a detailed analysis and summary of GRAS submissions from July to September 2025, to help enterprises stay informed and make strategic reference.
It is important to note that updates on the FDA website are often delayed – many substances may have already completed the GRAS review and received “no questions” letters, but their public status remains unchanged. CIRS Group closely monitors FDA updates, and this report summarizes the information newly released in Q3 2025.
